## Eva Lion

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3554237/publications.pdf

Version: 2024-02-01

218677 233421 2,451 45 49 26 citations h-index g-index papers 51 51 51 4141 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Clinical use of dendritic cells for cancer therapy. Lancet Oncology, The, 2014, 15, e257-e267.	10.7	565
2	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood, 2017, 130, 1713-1721.	1.4	170
3	Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs. , 2015, 146, 120-131.		134
4	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacological Reviews, 2015, 67, 731-753.	16.0	129
5	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. Journal of Hematology and Oncology, 2016, 9, 101.	17.0	96
6	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 164.	17.0	88
7	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Frontiers in Immunology, 2018, 9, 394.	4.8	84
8	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers, 2019, 11, 1597.	3.7	77
9	NK Cells: Key to Success of DC-Based Cancer Vaccines?. Oncologist, 2012, 17, 1256-1270.	3.7	76
10	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget, 2017, 8, 56968-56979.	1.8	59
11	Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. Oncolmmunology, 2015, 4, e1021538.	4.6	53
12	The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunology, Immunotherapy, 2010, 59, 35-46.	4.2	51
13	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	3.7	50
14	Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy, 2012, 14, 647-656.	0.7	49
15	The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses. Cells, 2020, 9, 1720.	4.1	49
16	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. Journal of Clinical Medicine, 2019, 8, 579.	2.4	48
17	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PLoS ONE, 2012, 7, e51851.	2.5	48
18	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS ONE, 2015, 10, e0123340.	2.5	47

#	Article	IF	CITATIONS
19	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget, 2017, 8, 89722-89735.	1.8	43
20	Transpresentation of interleukin-15 by IL-15/IL-15 $\hat{R}$ 1 mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget, 2015, 6, 44123-44133.	1.8	39
21	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. Cancer Immunology Research, 2017, 5, 710-715.	3.4	36
22	Human Tears Reveal Insights into Corneal Neovascularization. PLoS ONE, 2012, 7, e36451.	2.5	34
23	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. PLoS ONE, 2011, 6, e20952.	2.5	31
24	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. Hum Vaccin, 2011, 7, 579-584.	2.4	30
25	Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones. Frontiers in Immunology, 2021, 12, 668962.	4.8	30
26	CD56 marks human dendritic cell subsets with cytotoxic potential. Oncolmmunology, 2013, 2, e23037.	4.6	29
27	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. Frontiers in Immunology, 2018, 9, 2503.	4.8	29
28	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2013, 9, 1956-1961.	3.3	28
29	Engineering monocyte-derived dendritic cells to secrete interferon- $\hat{l}\pm$ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunology, Immunotherapy, 2015, 64, 831-842.	4.2	27
30	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine, 2022, 20, 124.	4.4	21
31	IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation. , 2017, 170, 73-79.		19
32	The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. Pharmaceutics, 2021, 13, 396.	4.5	18
33	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget, 2017, 8, 13652-13665.	1.8	18
34	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines, 2019, 7, 85.	4.4	17
35	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget, 2018, 9, 27797-27808.	1.8	17
36	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV â€positive tumour cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1372-1380.	3.6	16

#	Article	IF	CITATIONS
37	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. Cancers, 2019, 11, 1396.	3.7	13
38	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplantation, 2020, 55, 2308-2318.	2.4	12
39	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. Cancers, 2020, 12, 256.	3.7	12
40	Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN- $\hat{l}^3$ secretion by human NK cells. Leukemia Research, 2009, 33, 539-546.	0.8	11
41	Preexisting memory CD4 T cells in na $\tilde{A}$ ve individuals confer robust immunity upon hepatitis B vaccination. ELife, 2022, 11, .	6.0	11
42	Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study Journal of Clinical Oncology, 2014, 32, 7583-7583.	1.6	10
43	Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity. Immunogenetics, 2018, 70, 363-372.	2.4	8
44	Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. Methods in Molecular Biology, 2016, 1393, 27-35.	0.9	6
45	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. Blood, 2014, 124, 310-310.	1.4	5
46	Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia. Cancers, 2021, 13, 4519.	3.7	2
47	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Frontiers in Immunology, 2022, 13, 734256.	4.8	2
48	Interleukin-15 and Interleukin-15 Receptor $\hat{l}_{\pm}$ mRNA-engineered Dendritic Cells as Promising Candidates for Dendritic Cell-based Vaccination in Cancer Immunotherapy. Journal of Cancer Science & Therapy, 2016, 08, .	1.7	0
49	Loading of Acute Myeloid Leukemia Cells with Poly(I:C) by Electroporation. Methods in Molecular Biology, 2014, 1139, 233-241.	0.9	O